SeekingAlpha · Feb 18, 2026
AL
NASDAQ · ALLO
Allogene Therapeutics, Inc.
Healthcare · Biotechnology
$1.46
Down-$0.03 (-2.05%)
Updated Oct 8, 2026, 1:55 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 624.75M
- P/E ratio
- -2.91
- Dividend yield
- 0.00%
- 52-week range
- $1.04 – $4.46
- Volume
- 4.66M
- Avg. volume
- 4.59M
Price performance · ALLO
ALLO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ALLO closed at $1.46 after 20 trading sessions, down 15.61% for the selected period.
- Last close
- $1.46
- Period change
- -15.61%
- Period low
- $1.46
- Period high
- $1.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.50 | $1.50 | $1.43 | $1.46 | 4.66M |
| Oct 5, 2026 | $1.495 | $1.52 | $1.45 | $1.50 | 4.44M |
| Oct 2, 2026 | $1.57 | $1.5786 | $1.50 | $1.50 | 4.66M |
| Oct 1, 2026 | $1.60 | $1.61 | $1.53 | $1.54 | 4.61M |
| Sep 30, 2026 | $1.61 | $1.66 | $1.58 | $1.60 | 8.13M |
| Sep 29, 2026 | $1.60 | $1.645 | $1.60 | $1.62 | 4.32M |
| Sep 28, 2026 | $1.65 | $1.665 | $1.60 | $1.63 | 5.03M |
| Sep 25, 2026 | $1.69 | $1.695 | $1.63 | $1.65 | 3.62M |
| Sep 24, 2026 | $1.67 | $1.72 | $1.60 | $1.67 | 7.79M |
| Sep 23, 2026 | $1.73 | $1.74 | $1.65 | $1.67 | 5.97M |
| Sep 22, 2026 | $1.72 | $1.74 | $1.6829 | $1.71 | 5.24M |
| Sep 21, 2026 | $1.71 | $1.72 | $1.645 | $1.69 | 5.99M |
| Sep 18, 2026 | $1.73 | $1.74 | $1.67 | $1.69 | 12.72M |
| Sep 17, 2026 | $1.74 | $1.765 | $1.70 | $1.73 | 3.95M |
| Sep 16, 2026 | $1.74 | $1.77 | $1.66 | $1.69 | 5.65M |
| Sep 15, 2026 | $1.80 | $1.80 | $1.71 | $1.72 | 3.14M |
| Sep 14, 2026 | $1.775 | $1.84 | $1.765 | $1.78 | 7.75M |
| Sep 11, 2026 | $1.80 | $1.805 | $1.7541 | $1.78 | 3.89M |
| Sep 10, 2026 | $1.73 | $1.78 | $1.695 | $1.76 | 5.4M |
| Sep 9, 2026 | $1.85 | $1.875 | $1.72 | $1.73 | 7.28M |
Latest ALLO news
The latest Smart Investors Daily articles mentioning ALLO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALLO research
Overview
Company profile and research snapshot.
Company profile
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Citizens | Market Outperform | — |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 16, 2026 | JP Morgan | Neutral | — |
| Apr 15, 2026 | Jefferies | Buy | — |
| Apr 14, 2026 | Bernstein | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Jan 9, 2026
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Yahoo · Jan 8, 2026
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Dise
globenewswire.com · Nov 10, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
